Tirzepatide

Compound Overview

Tirzepatide is a first-in-class dual incretin receptor agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. By engaging both pathways, it gives researchers a way to examine the combined signaling behavior of two major metabolic hormone systems in controlled laboratory studies.

Research Background & Published Literature

Published findings from the SURPASS and SURMOUNT clinical trial programs have increased research interest in dual incretin pathway signaling. Tirzepatide studies have helped expand the literature around how paired GIP and GLP-1 receptor activation may differ from GLP-1-only approaches in metabolic research models.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Coskun et al. (2018) — Mol Metab
• Willard et al. (2020) — JCI Insight
• Rosenstock et al. (2021) — Lancet
• Jastreboff et al. (2022) — N Engl J Med

Storage, Handling & Stability Guidelines

Store lyophilized Tirzepatide at -20°C. After reconstitution, aliquot and store at 2–8°C. Use reconstituted material within 21 days for optimal stability.

• Keep ambient-temperature handling time brief to help preserve compound integrity.
• Reseal vials promptly after each withdrawal to reduce moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with the compound name, concentration, date of reconstitution, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.